Bio B2B 〉 Selective Search Results
Your Selection Setting ：Analytics & Detection； Anti-Body； Delivery； Fermentation； Formulation； Glycan-based； Microbiota； Peptide； Purification； Synthesis；
Selective Search Results :
Pipeline & Platform 45 record(s)；
Vitamin D Analogs (up to 500 gram batch size)Steroids (up to 65 kilo batch size)Cytotoxics (up to 16 kilo batch size)
Pilot scale up development and manufacturing
The R&D Center has a testing center and various laboratories specializing in drug formulation, Chinese medicine, microorganisms, and cellular and molecular biochemical functions. By using precision instruments and technologies and gathering experts from different fields, the R&D Center offers a comprehensive range of services for product inspection, research and development, and improvement
Scale up development & manufacturing
Small Molecule Drugs
ScinoPharm possesses a full range of chemistry capabilities and has extensive experience in synthesizing complex molecules. Depending on individual requirements, we develop new synthetic routes, or scale up and optimize processes based on the customer's technology. Our synthesis studies include structured Design of Experiment. (DoE) methods used to identify optimal conditions, factors that most
Establish target product profile (TPP) to establish go/no go criteria for IND enabling studies. We adopt a reiterative evaluation process using multiple in vitro and in vivo SC xenograft models, transgenic and humanized mouse models and/or syngeneic models to conduct PK/PD and toxicology studies to identify the best preclinical candidates.
Chemistry Manufacturing and Controls (CMC)
1. Cell line development2. Process development3. Analytical method development4. Quality control and quality assurance system development5. Production technology, purification techniques, quality analysis and stability studies
Deploy multiple strategies to improve binding affinity and efficacy of lead antibodies. Utilize biochemical and biophysical characterization to profile the lead antibodies. Conduct exploratory in vivo experiments to rank order potential leads for optimization. Utilize multiple in vivo PK/PD models and a broad range of tumor models to benchmark our lead antibodies with current standard of care and/or
Core Technology: Pegylation PlatformIn the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in
ScinoPharm provides comprehensive peptide synthesis technologies with full analytical and regulatory support. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, ScinoPharm can design and develop higher yield processes for larger-scale peptides that are scalable and more cost effective, ensuring faster time-to-market.Peptide Synthesis CapabilitiesSynthesis
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively targeted therapies, these nanomedicines are better able to
TAH4411 Antiemetic Oral Thin Film
TAH4411 oral dissolving film (ODF) is a new formulation of a selective 5-HT3 receptor antagonist which blocks stimulation on both peripherally located vagal nerve terminals and centrally located receptors in the chemoreceptor trigger zone of the area postrema.This new formulation provides equivalent amount of the active ingredient as in Zofran® tablets and Zofran® OD tablets, but with a potential
TAH9901 ADHD Trandermal Patch
TAH9901 comprise of a ADHD treatment proven to be safe and efficacious for over 50 years, and as a stimulant, is a first line therapy for children with ADHD. TAH 9901 offers a transdermal once daily treatment for ADHD.Uniqueness:• Reducing dosing frequency due to longer duration• Improved bioavailability• Uniform plasma levels, resulting in reduced side effect• Possibility of terminating
TAH9922 ADHD Oral Solution
TAH9922 is an once-daily, liquid ADHD treatment option. It is a flavored, immediate release ADHD treatment option for patients ages 6 and above. Dosing can be tailored to the treatment's need.Uniqueness:• Better Palatability• Improved patient compliance via non-invasive, painless and simple application
AmCAD-CA, specially designed for microscopy cytology is the only commercially available software specifically designed for cytopathology analysis. AmCAD-CA features visualization and quantification of clinical characteristics, such as nucleus size, circularity, polarity and elongation, nuclear-cytoplasm ratio, inclusion bodies, etc, for cytology microscopic images, aiding professionals in biological
Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
CHO-A04 is a humanized monoclonal antibody targeting a novel carbohydrate antigen specifically and highly expressed on more than 10 cancer types, including triple negative breast cancer (TNBC) and pancreatic cancer. CHO-A04 kills cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The proof-of-concept (POC) study for CHO-A04 has been well
ScinoPharm offers world class services related to the development and manufacturing of clinical, small-scale, and commercial-stage active pharmaceutical ingredients (APIs) and intermediates. Dedicated Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) are to provide fast response to customers' needs, combined with a flexible, reliable, and competitive approach.With
CX-4945: CK2 Inhibitor Program
CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents. Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination
Synthetic lethality (SL) is a concept in which cell death is induced by the combination of two non-lethal mutations, while mutation alone is not sufficient to affect cell survival. Recently, SL has been proposed as a novel anticancer strategy that is promising to be highly selective. If a cancer-specific mutation combined with a drug-induced mutation have SL interactions, it will selectively
CX-5461: RNA Polymerase I (Pol I) Inhibitor Program
The p53 protein normally functions as a tumor suppressor by causing cancer cells to self-destruct. Activating p53 to kill cancer cells is a well validated anticancer strategy and many approaches are being employed to exploit this pathway. By targeting RNA Polymerase I (Pol I) to activate p53 in cancer cells but not normal cells, through the nucleolar stress pathway, Senhwa's first-in-class
Dual-targeted bifunctional anti-flu drug (CHO-S05)
A novel series of dual-targeted bifunctional anti-flu drugs comprising of influenza virus inhibition and pro-inflammatory cytokine suppression are designed, synthesized and evaluated. In vitro and in vivo functional analyses have shown remarkable protection of cells and mice by oral administration against H1N1 & H5N1 influenza viruses.
FB825 is a humanized monoclonal antibody that binds to the CεmX domain, leading to death of the membrane IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in a dosing-dependent manner. FB825 can stand alone as a monotherapy or in combination with Xolair for the treatment of allergic asthma and IgE-mediated diseases.
Glycan arrays and glycoprobes
Synthetic oligosaccharides and/or polysaccharides are immobilized on a solid supported in a spatially-defined arrangement to mimic the glycan expression on cell surface. The arrays of various glycans can be used for the diagnosis and prognosis of the disease such as cancer and infectious disease. They can also be used as research tools such as the validation of glycan binding protein and antibody,
Homogeneous antibody drugs (CHO-H01, H02, H03)
A unique glycan structure was identified for monoclonal antibodies with improved activity. With the proprietary technology developed by CHO Pharma, the Fc-glycan structure of therapeutic antibodies can be engineered to a homogeneous glycoform, which displayed enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC), in vivo anti-tumor activities, and potential anti-inflammatory properties
Injectable Manufacturing Services
Already the leader in providing oncological APIs to regulated markets worldwide, ScinoPharm is poised to extend the service to offer finished dosage form of injectable products. With the completion of injectable plant in Tainan campus in Taiwan and combining the API capability, ScinoPharm is able to provide integrated solutions for one-stop shopping of injectable products in a flexible, reliable and
Maximize lead discovery efficiency using multiple approaches such as proprietary naïve human phage display library with a diversity of 1.5E+10, and conventional hybridoma technology. Developed robust screening criteria utilizing multiple in vitro assays established for each project to evaluate selectivity, affinity and potency of multiple leads.
MS-20 is a mixture of soy fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics human intestinal environment.The manufacturing and R&D procedures of Chemo Young follow the international regulations.MS-20 was approved as new drug by TFDA in 2011.MS-20 acts as an immunemodulator and probiotics to improve immunity and
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
Newborn genetic screening for hearing impairment using real-time PCR with FRET probes
Hearing Loss, about 2 / 3 can be attributed to genetic mutations, is the most common congenital defects, so genetic testing has become a powerful tool for the clinical assessment. Around 75–80% of all cases are inherited by recessive genes, 20–25% is inherited by dominant genes, 1–2% is inherited by X-linked patterns, and less than 1% is inherited by mitochondrial inheritance. Through
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
NanoX™ technology uses nanoparticles coated with the compound polyethylene glycol to reduce uptake by phagocytic cells of the immune system. This prolongs circulation in the body, allowing a drug to predominantly accumulate at particular disease sites such as tumors. Therapies based on NanoX™ technology can also make use of additional molecular coatings to help nanoparticles to accumulate
Quantitative analysis of SMN1 and SMN2 genes based on DHPLC
Autosomal recessive spinal muscular atrophy (SMA) is a common, fatal neuromuscular disease caused by homozygous absence of the SMN1 gene in approximately 95% of patients. However, a highly homologous SMN2 gene exists in the same chromosome interval, centromeric to SMN1, and hampers detection of SMN1. We develop a rapid, simple, and highly reliable method for detecting the SMN1 deletion/conversion and
RNTA06 is used to treat angina. R06 can response the demand from angina treatment market, with good safety profile. Considering the high entry barrier of development, we believe R06 can create significant value from the market.
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting
IndicationAnalgesic and antipyreticAdvantages Over Current ProductHepatotoxicity-freeTo address the important and urgent unmet medical needsA patented formulation with great safety marginPotential MarketAcetaminophen sales are 1.3 billion USD a year (US only)Competitive EdgeCurrently, no hepatotoxicity-free acetaminophen on the marketGreat impact on the market share of pain controllers, especially
IndicationHepatotoxicity-free AnalgesicAdvantages Over Current ProductHepatotoxicity-free Acetaminophen prescription ComboA new combination with great safety marginPotential MarketAcetaminophen prescription Combo sales are 2.7 billion USD a year (US only)Competitive EdgeNo hepatotoxicity-free acetaminophen prescription Combo on the marketAcetaminophen prescription combos were requested by USFDA
TAH8801 Alzheimer's Disease Transdermal Patch
TAH8801 is a once a day transdermal patch system used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments. The patch releases medicine continuously over 24 hours. The medication is absorbed through the skin and may be an option for those who have trouble swallowing pills.Uniqueness• Reducing dosing frequency due to longer duration• Improved bioavailability&bull
low-alcohol formulation (iLEF) platform
Intech Biopharm focus on new dosage, new combination, new delivery and high barrier generic drug development and manufacturing for respiratory therapy area. We are currently one of the leading companies, and the only one in Taiwan, that can provide and manufacture high barrier obstructive airway diseases drug and our competitive advantage are as follow: iLEF platform: It has a low-alcohol